ZYCOV-D
ZYCOV-D Uses, Dosage, Side Effects, Food Interaction and all others data.
The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India. The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest. Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune system. The DNA vaccine platform offers minimal biosafety requirements, more improved vaccine stability, and lower cold chain requirements. Phase I clinical trials of this vaccine candidate were completed in July 2020, with the company reporting successful dosing and tolerance. As of August, 2020 the candidate is in Phase II clinical trials.
| Trade Name | ZYCOV-D |
| Generic | ZYCOV-D |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here ZYCOV-D
